Dev Drugs (India) Private Limited, a active private limited company, was established on 23 October 1996 in New Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U65929DL1996PTC082829. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹2.50 M and a paid-up capital of ₹1.60 M.
Formerly known as Noni Gopal Infinlease Private Limited. It upholds a compliant status. Employing 7 professional, Its leadership includes Subrata Roy (Director), Balbir Singh (Director). Past directors included Mitali Roy, Subrata Roy, Rabindra Kumar Bishwas. It holds ₹8.50 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at D-67 Pandav Nagar, Patparganj, New Delhi, Delhi, 110092.
U65929DL1996PTC082829
082829
23 October 1996
₹2.50 M
₹1.60 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Dev Drugs (India) Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Subrata Roy | Director | 14 Sep 2021 | Current |
| Balbir Singh | Director | 15 Sep 2020 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 14 Sep 2021 | Past |
| Pramod Abcsdd | Additional Director | 30 Nov 2021 | Past |
| Pramod Abcsdd | Director | 08 Apr 2021 | Past |
| Pramod Abcsdd | Director | 15 Sep 2020 | Past |
| Pramod Abcsdd | Additional Director | 31 Dec 2020 | Past |
| Pramod Abcsdd | Director | 16 Sep 2020 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Dev Drugs (India) Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 43.04% decrease. The company also saw a substantial fall in profitability, with a 185.76% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.5%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Dev Drugs (India) had a public holding of 6.24%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹85,028,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 May 2025 | Sidbi | ₹2.55 Cr | Open |
| 29 Mar 2023 | Sidbi | ₹2.65 Cr | Open |
| 30 Mar 2022 | Sidbi | ₹2.00 Cr | Open |
| 03 Nov 2020 | Sidbi | ₹1.30 Cr | Open |
Explore comprehensive loan charge details -
Dev Drugs (India) has a workforce of 7 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Dev Drugs (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dev Drugs (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Dev Drugs (India) Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was completed.
The activity A charge with Sidbi amounted to Rs. 25.50 M with Charge ID 101100671 was registered on 22 May 2025. was completed.
Dev Drugs (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi. was recorded as a recent event.
A charge with Sidbi amounted to Rs. 26.50 M with Charge ID 100703582 was registered on 29 Mar 2023. was recorded as a recent event.
A charge with Sidbi of Rs. 13.03 M registered on 03 Nov 2020 with Charge ID 100382532 was modified on 25 Mar 2023. was recorded as a recent event.
A charge with Sidbi amounted to Rs. 20.00 M with Charge ID 100552164 was registered on 30 Mar 2022. was recorded as a recent event.
The CIN of Dev Drugs (India) Private Limited is U65929DL1996PTC082829.
Dev Drugs (India) Private Limited is headquartered at D-67 Pandav Nagar, Patparganj, New Delhi, Delhi, 110092.
Dev Drugs (India) Private Limited was incorporated on 23 October 1996.
The current directors of Dev Drugs (India) Private Limited are
The primary industry of Dev Drugs (India) Private Limited is Manufacturing.
Dev Drugs (India) Private Limited is unlisted.
The authorized capital of Dev Drugs (India) Private Limited is ₹2.50 M, and the paid-up capital is ₹1.60 M.
The compliance status of Dev Drugs (India) Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX